In Vivo Performance and Biocompatibility of the MagScrew Ventricular Assist Device

Schenk, Soren; Weber, Stephan; Luangphakdy, Viviane; Flick, Christine R.; Chen, Ji Feng; Inoue, Masahiro; Kopcak, Michael W.; Ootaki, Yoshio; Doi, Kazuyoshi; Dessoffy, Raymond; Hirschman, Gordon B.; Vitale, N.; Chapman, P. A.; Smith, William A.; Fukamachi, Kiyotaka

doi:10.1097/01.mat.0000084107.46300.21

Cited by 9 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described elsewhere (2,3), the MagScrew TAH system is fully implantable and has the flexibility to be powered by either an implantable battery pack, an EBP, or a transcutaneous energy transmission system. The implantable battery enables tether‐free operation for up to 90 min at nominal conditions of flow 5–6 L/min, 100 mm Hg aortic pressure (AOP), and 20 mm Hg pulmonary arterial pressure (PAP).…”

Section: Methodsmentioning

confidence: 99%

Cycle Testing of the MagScrew Total Artificial Heart External Battery Pack: Update I

et al. 2010

Self Cite

View full text Add to dashboard Cite

MagScrew total artificial heart (TAH) external battery pack (EBP) cycle bench testing continued over a period of 18 months using two fresh Wilson Greatbatch lithium ion EBPs during continuous charge and discharge cycles under a simulated TAH system current requirement. The same electronic load developed for our initial testing was used to simulate the MagScrew current waveforms typically observed during nominal operation. The current load profiles for this test were modified from the ones previously described and applied to the EBP under test during a voltage-defined discharge cycle. The test ended when EBP#2 reached end of life at 1450 cycles. At that point, EBP#1 remained healthy with a capacity of 175 min until full discharge. Performance of EBP#2 was still within expected ranges. Performance of EBP#1 exceeded expectations. These differences are probably caused by slight manufacturing changes. More tests will provide additional data to define a statistical distribution to better characterize EBP performance. In conclusion, endurance performance of the EBP remained satisfactory.

show abstract

Section: Methodsmentioning

confidence: 99%

Cycle Testing of the MagScrew Total Artificial Heart External Battery Pack: Update I

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…The implantable battery enables tether free operation for up to 90 min at nominal conditions of flow 5-6 L/min, 100 mm Hg aortic pressure (AOP), and 20 mm Hg pulmonary arterial pressure (PAP). More details of the system are provided elsewhere (1)(2)(3)(4). The MagScrew TAH system includes two battery systems: (i) the IBP and (ii) the EBP.…”

Section: System Descriptionmentioning

confidence: 99%

Cycle Testing of the MagScrew Total Artificial Heart External Battery Pack

et al. 2007

Self Cite

View full text Add to dashboard Cite

MagScrew total artificial heart (TAH) external battery pack (EBP) cycle bench testing was conducted on two Wilson Greatbatch (Clarence, NY, USA) lithium ion EBPs over a period of 22 months during continuous charge and discharge cycles under a simulated TAH system current requirement. A custom electronic load was developed to simulate the MagScrew current waveforms typically observed during nominal operation. These current load profiles were applied to the EBP under test during a voltage-defined discharge cycle. EBP endurance indicated a 240-min discharge cycle on a new battery diminishing linearly to 175 min after 800 cycles. A second linear trend started at this knee with 150 min of discharge time at 850 cycles until 10 min at 1600 cycles. Even at 1300 cycles, the EBP could still provide enough power for 60 min of nominal operation. In conclusion, the endurance performance of this EBP was satisfactory while exhibiting a predictable wear-out trend.

show abstract

“…Lastly, we reported the outcome of an in vivo evaluation of the MagScrew VAD and TAH (57). The protein‐coated “biolized” blood‐contacting surface of MagScrew VAD was designed to prevent clot formation.…”

Section: Effect Of Device Typementioning

confidence: 99%

In Vivo Preclinical Anticoagulation Regimens After Implantation of Ventricular Assist Devices

Saeed¹,

Fukamachi²

2009

Artificial Organs

Self Cite

View full text Add to dashboard Cite

Ventricular assist devices (VADs) have demonstrated successfully their ability to treat failing circulation of patients with end-stage heart failure. Among the main obstacles with these VADs is thromboembolic events that increase device-related morbidity and mortality. Prior to the clinical application of any newly developed VAD, the feasibility of the device is tested on animal models. Animal species have different hemostatic properties than human patients, and this factor creates a margin of error when comparing the occurrence of VAD-induced thrombosis in an animal versus a human. This detailed literature review provides a thorough documentation of various preclinical anticoagulation protocols used to date, including their outcomes and recommendations for future anticoagulation management strategies. In summary, the outcomes favor a sheep or pig model over other animal models, and discourage the application of a single anticoagulative agent to improve outcomes with any of the currently available devices.

show abstract

In Vivo Performance and Biocompatibility of the MagScrew Ventricular Assist Device

Cited by 9 publications

References 7 publications

Cycle Testing of the MagScrew Total Artificial Heart External Battery Pack: Update I

Cycle Testing of the MagScrew Total Artificial Heart External Battery Pack: Update I

Cycle Testing of the MagScrew Total Artificial Heart External Battery Pack

In Vivo Preclinical Anticoagulation Regimens After Implantation of Ventricular Assist Devices

Contact Info

Product

Resources

About